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Summary The peak incidence of Hodgkin's disease occurs during the reproductive age, and its association
with pregnancy is at a rate of between 1:1,000 - 1:6,000. We studied the effects of Hodgkin's Disease on the
course and survival of 48 women who had Hodgkin's Disease and who were pregnant, and compared their
outcome with non-pregnant matched women who were of similar stage of disease, age at diagnosis, and
calenderic year of treatment. Twenty-year survival of pregnant women with Hodgkin's Disease was not
different from that of their matched controls. Pregnant women with Hodgkin's Disease had similar distribu-
tion of stages to the controls.
Because the peak incidence of Hodgkin's Disease (HD) is in
the age range 20-40 years, its association with pregnancy is
not uncommon, occurring in 1:1,000-1:6,000 deliveries
(Ward & Weiss, 1989). Early studies reported a higher fre-
quency of relapse and lower survival rates in HD patients
who were pregnant (Southman et al., 1956). Later publica-
tions rejected this conclusion, claiming that pregnancy
neither exacerbates the disease nor adversely affects survival
(Stewart & Monto, 1952; Riva et al., 1953; Barry et al., 1962;
Gobbi et al., 1984; Tawil et al., 1984; Nisce et al., 1986). The
view that pregnancy does not affect the course of Hodgkin's
disease and the disease does not affect the course of preg-
nancy has become widely accepted and repeatedly stressed in
reviews and textbooks (Ward & Weiss, 1989; Sutcliffe &
Chapman, 1985; Becker, 1968). However, this conclusion is
based on single cases or a surprisingly small number of
uncontrolled studies (Barry et al., 1962; Gobbi et al., 1984;
Tawil et al., 1984; Nisce et al., 1986).
It is unlikely that prospective controlled studies will ever
be undertaken to further explore the interaction between HD
and pregnancy; therefore, we performed an historical cohort
study to evaluate the influence of pregnancy on HD and that
of HD on pregnancy among women treated at the Princess
Margaret Hospital (PMH) between 1958-1984. To the best
of our knowledge, this is the only controlled study of HD
and pregnancy. In addition, this study is unique in providing
information on foetal outcome.
Methods
All patients with histologically confirmed Hodgkin's disease,
registered in the Princess Margaret Hospital between
1958-1984 were identified. PMH is an oncologic hospital
serving the Province of Ontario. Cases with HD in pregnancy
were identified by extracting from the database all women
who had HD, where the woman was pregnant within 9
months prior to or 3 months after the first treatment. Based
on the assumption that cancer would be present for some
time before it could be diagnosed, 9 months was chosen to
reflect the normal gestational period and 3 months was
chosen arbitrarily to make the width of the time frame 1
year. The day of the first treatment was used only to extract
the patients from the database because dates of diagnosis
were not always recorded in the Princess Margaret Hospital
(PMH) computer. For the purposes of the study, the date of
diagnosis was used as a reference date after the charts had
been examined. Potential cases were further screened by
examining their charts to verify that pregnancy and HD
occurred within the time frame stated above and to reject
patients who had an ectopic pregnancy.
To study the effects of pregnancy on the course of HD, we
matched women having HD in pregnancy to non-pregnant
women with the disease. For each pregnant case, an attempt
was made to identify three matched controls in the PMH
database according to the following criteria:
(1) The control women had to be within 2 years of age of
the pregnant cases at diagnosis and could not have
been pregnant within 15 months prior to or 9 months
after first treatment.
(2) Controls had the same Ann Arbor stage of HD as
cases at diagnosis (Hermanek & Sobin, 1987).
(3) Controls had the same presence or absence of B symp-
toms as cases at diagnosis (fever, night sweats, and/or
weight loss of more than 10% of the original weight 6
months prior to first attendance).
(4) Controls were diagnosed within 2 calenderic years of
the associated case. It was assumed that controls would
have similar staging procedures and treatment proto-
cols as the cases if controls were of same age, stage,
and calendaric year of diagnosis as the cases. The
validity of this assumption was verified in a random
sample of ten pregnant women and 23 controls and
was true 96% of the time.
Data describing patient characteristics with HD including
date of diagnosis, staging, and presence or absence of B
symptoms were extracted from the charts of both cases and
controls. Dates and types of treatment, including treatment
delays, were also recorded. Obstetrical information, including
date of conception, gestational age at diagnosis and at first
treatment, complications in pregnancy and its outcome were
also recorded.
For cases whose pregnancies continued to term or resulted
in stillbirth, birth records were requested from the delivering
hospital. For live births, sex and birth weight of the infant
were recorded, as well as gestational age at delivery, type of
delivery, foetal complications and congenital anomalies. For
intrauterine death, date of diagnosis of the stillbirth and
autopsy results were collected.
Live births were compared to those of infants born to
women attending the Motherisk Program at The Hospital for
Sick Children in Toronto, following exposure to drugs,
chemicals, or radiation during the first trimester of pregnancy
(Koren & MacLeod, 1986). For this analysis, each mother
with HD was matched to a mother of similar age who was
exposed to non-teratogenic drugs or chemicals.
Statistical analysis
Cause-specific survival curves were produced using the
Kaplan-Meier estimate (Kaplan & Meier, 1958). For the
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purposes of this paper, cause-specific survival is defined as
mortality due to the disease under investigation. Any death
caused by other than the disease under investigation is
treated as censored. The Mantel-Haenszel logrank test was
employed to test for differences between survival curves (Peto
et al., 1977). A chi-square test was utilised to compare the
distribution of stages upon diagnosis between the cases and
the non-pregnant women having HD during the reproductive
age registered in the PMH database and to verify that the
crtieria for matching was similar in cases and controls. The
Bonferroni method was used to adjust for multiple com-
parisons. Fisher's exact test was used to compare the effect of
stage on maternal outcome between cases and controls.
Foetal outcome values between the study and control groups
were compared using a two-sided Student's t-test for
independent samples and chi-square tests whenever appropri-
ate. The odds ratio was used to estimate the relative risk of
pregnant women with HD to have a stillbirth compared to
pregnant woman without cancer having a stillbirth in the
province of Ontario (Schlesselman, 1982). The observed
number of stillbirths was assumed to follow a Poisson distri-
bution. Statistical analysis was performed with the aid of
SAS version 5.1 and Minitab release 6.1.1.
Results
Forty-eight women with HD and pregnancy were identified
in the PMH database between 1958-1984. Two women had
two pregnancies, each fitting in the time frame of the study,
resulting in 50 pregnancies in 48 women. The mean age of
women with HD was 26.1 +/ - 4.9 years (median 25 years
and a range of 18 to 38 years). Of the 50 pregnancies, 12
(24%) were diagnosed with HD before conception, 10 (20%)
during pregnancy, and 27 (54%) were diagnosed after
delivery or pregnancy termination. For one pregnancy this
information was unavailable.
Treatment modalities of the 48 women included
radiotherapy alone (n = 31), chemotherapy alone (n = 6),
and combined radiotherapy and chemotherapy (n = 11). Of
those women diagnosed before or during the pregnancy
(n = 22), 16 women received radiation while pregnant, one
received chemotherapy during the first trimester, and five
received combination chemotherapy and radiotherapy while
pregnant. One patient delayed treatment due to pregnancy.
She had received radiotherapy while pregnant and delayed
chemotherapy until after delivery.
Of the 48 cases, 67 matched controls were found for 33
women. Three controls per patient could not always be
obtained because of the selectivity of the matching criteria.
For 15 cases, matched controls could not be found. This
unmatched group was not statistically significantly different
from the matched group when compared by survival
(P = 0.6).
Maternal outcome
Using a cause-specific Kaplan-Meier survival curve, the 20-
year survival of the 33 cases was compared to their 67
matched controls (Figure 1). No statistically significant
difference was found between these groups (P = 0.6). At the
time of the study, eight of the cases had died of HD while
the remaining 25 were either alive or died of other causes. In
the control group, 12 women died of HD.
We subsequently compared survival in the subgroup of
patients who were diagnosed with HD prior to conception or
during the pregnancy and had matched controls (n = 17)
with their matched controls. No statistical difference was
found (P = 0.6).
When the effect of individual stage of HD on maternal
survival was analysed, no significant differences were found
between cases and controls (P >0.1 for each comparison).
To evaluate whether increasing age at diagnosis had an
adverse impact on maternal cause-specific survival, we com-
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Figure 1 Kaplan-Meier cause-specific survival curve for Hodg-
kin's disease comparing women who were pregnant and had
Hodgkin's disease (n = 33) with matched, non-pregnant controls
(n=67). P =0.6.
pared cases above (n = 26) to cases below (n = 22) the
median age of 25. No statistically significant difference was
found (P = 0.32).
In an attempt to verify whether pregnancy affected the
stage of HD upon diagnosis, we compared the distribution of
stages between our cases with that of non-pregnant women
younger than 38 years registered in the PHM database dur-
ing the same time period (1958-1984). Of the 48 pregnant
women, 12 (25%) had stage 1 disease at diagnosis, 22
(45.8%) stage 2, 8 (16.7%) stage 3, and 6 (12.5%) had stage
4. Of the 529 non-pregnant women identified in the com-
puterised database, 79 (15%) had stage 1 disease, 257 (49%)
stage 2, 106 (20%) stage 3, and 87 (16%) had stage 4. No
statistically significant difference was found between these
two distributions (P >0.25, after adjusting for multiple com-
parisons).
Pregnancy outcome
Of the 50 pregnancies studied, there were 40 deliveries (two
of which were stillbirths), five miscarriages, and four
therapeutic abortions. The outcome of one pregnancy was
unknown.
Of the 38 live births, we were able to obtain 22 obstetrical
records and two autopsy reports from the delivering hospitals
(the remaining were unavailable due to unidentified deliver-
ing hospitals, destroyed birth records, or refusal to release
confidential documents). However, in some additional cases,
the maternal charts reported details of pregnancy outcome
(Table I).
No differences were found between the babies born to
women with HD when compared to the Motherisk matched
controls in birth weight (P = 0.7), mean gestational age
(P = 0.3) or method of delivery (P = 0.5). One malformation
was identified: This was a child with hydrocephaly born to a
mother whose HD was diagnosed before conception. She was
treated only by combination chemotherapy (MOPP - Nit-
rogen mustard, Oncovin, Prednisone, Procarbazine) during
the first trimester.
Of the 22 babies born and exposed in utero to HD therapy
(n = 15), one was exposed to chemotherapy during the first
trimester of pregnancy, one was exposed to chemotherapy
and radiation after the first trimester, six were exposed to
radiation during the first trimester of pregnancy, and seven
were exposed to radiation after the first trimester.
We compared the number of stillbirths in our group (two
per 40 total births) to that of the general population of
Ontario (11.3 stillbirths per 1,000 total births) (Province of
Ontario Vital Statistics, 1960-1984). The difference was not
statistically significant (P = 0.076).
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Table I Comparison of foetal outcome in mothers with Hodgkin's disease to the matched control
group (n = 38)a
n Study babies n Matched contol babies
Gestational age 29 39.7+1- 1.0 37 40.0 +-1.8
(weeks)
Number ofpreterm 29 1 37 1
births (<37 weeks)
Birth weight (g) 21 3325 + 529 37 3371 + 474
Delivery method 25 20 spontaneous 5 caesarean 38 32 spontaneous 6caesai-ean
Malformations 31 1 case ofhydrocephaly, baby 38 None
died 4 h after birth
Stillbirth 40 2 38 None
aPlus-minus values aremeans +/ - SD.
Discussion
The diagnosis of HD in pregnancy puts immense stress on
pregnant women, their families and on physicians caring for
them. Potential harm to the woman from delayed diagnosis,
staging or therapy, and the risk to the baby from radiation
or chemotherapy creates serious pressure and a need for
prompt decisions. For such choices to be authoritative, they
must be based on large experience, which is lacking in any
particular centre due to the relative rareness of the combina-
tion of HD and pregnancy.
Most published studies suffer from major problems that
make them difficult to interpret and cast doubt on their
validity. First, some of the frequently references studies were
performed decades ago (Stewart & Monto, 1952; Barry et al.,
1962; Kadson, 1949; Bichel, 1950; Myles, 1955). Since the
diagnostic tools, staging methods, and especially treatment
modalities have progressed tremendously in recent years, it is
difficult to extrapolate these results to the present time.
Second, most studies do not compare matched controls but
rather compare pregnant women with a nonmatched cohort
of nonpregnant women with HD (Barry et al., 1962; Gobbi
et al., 1984). Such reports carry a substantial risk of bias
since the groups compared may be unbalanced for significant
prognostic factors and thus the analysis may be misleading.
Finally, some papers provide case reports or a summary of
an experience with a small number of patients (Howard et
al., 1978; Jacobs et al., 1981; Morgan et al., 1976). Although
these reports are important, they cannot be used as guidelines
for a rational clinical approach for these patients. In contrast
to previous work, our study is the first to use a case-control
method to study the outcome of pregnant women with HD.
It is based on a significant number of patients that were
carefully matched for the recognised and important prognos-
tic factors of HD (Ward & Weiss, 1989). In addition, patients
and controls were staged according to modern recommenda-
tions.
Our study did not detect an effect of pregnancy on survival
of women with HD, as their long term prognosis was iden-
tical to that of their matched controls. Moreover, this
analysis reveals that the pregnant women is not more likely
to be at a higher stage (more advanced disease) than women
of reproductive age in general. This indicates that pregnancy
is not likely to change the biology of the tumour or to
postpone diagnosis. These results are in contrast to our
findings with breast cancer, where pregnant women have a
significantly higher risk of being diagnosed with metastatic
disease (stage 4) (Zemlickis et al., in press).
Our study is the first to provide data regarding foetal
outcome by analysing infants born to women with HD dur-
ing pregnancy. We found that infants born to women with
HD did not have a higher risk for prematurity or intrauterine
growth retardation. Conversely, babies born to women with
breast cancer have been shown by us to suffer from a
significant small for gestational age (SGA) risk (Zemlickis et
al., in press). The rate of stillbirth was not statistically
different from data for Ontario. This may reflect a beta error
due to a small sample size, and larger numbers will be needed
to confirm it.
Although various chemotherapeutic agents have been suc-
cessfully administered during early pregnancy (Nisce et al.,
1986; Thomas & Peckham, 1976), there is compelling
evidence that chemotherapy has significant likelihood of
adversely affecting the baby during embryogenesis (Lishner &
Koren, in press). The only infant in this series born to a
patient who received chemotherapy during the first trimester
(MOPP-Nitrogen Mustard, Oncovin, Prednisone, Procar-
bazine) had hydrocephaly and died in early infancy. In con-
trast, there is no evidence for teratogenic effect of
chemotherapy delivered during second or third trimester of
pregnancy (Koren et al., 1990; Lishner & Koren, in press). In
our series, one baby was exposed to chemotherapy after the
first trimester and was normal at birth. Much more data are
needed to define the relative foetal risk of chemotherapy
during embryogenesis as well as later.
In summary, this study could not detect adverse effects of
pregnancy on survival of women with HD. Similarly, preg-
nant women are not likely to be at a higher stage of their
disease than their matched controls.
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